Perspective Therapeutics announced that the U.S. Food and Drug Administration, FDA, granted Fast Track Designation for the development of 212Pb VMT01 for the diagnosis and treatment of patients with unresectable or metastatic melanoma and who have demonstrated MC1R tumor expression. Melanocortin 1 receptor, or “MC1R,” is a protein that can be overexpressed in metastatic melanoma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics participates in a webinar with Cantor Fitzgerald
- Mark Austin Steps Down from Executive Roles at Perspective Therapeutics
- Perspective Therapeutics to Participate in Upcoming Investor Conferences in September
- Perspective Therapeutics Announces Executive Financial Reorganization
- Perspective Therapeutics price target lowered to $27 from $29 at RBC Capital